Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03349476
Other study ID # 17-02-329
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date April 16, 2018
Est. completion date October 3, 2022

Study information

Verified date November 2023
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, multicenter observational study will examine the ability of model based fast anatomical mapping (mFAM) to create left atrial (LA) geometry for atrial fibrillation ablation.


Description:

This prospective, multicenter observational study will examine the ability of model based fast anatomical mapping (mFAM) to create left atrial (LA) geometry for atrial fibrillation ablation. Specifically, the study will assess the following issues in atrial fibrillation ablation: 1. Accuracy of map (defined as the distance between the ablation points and the surface of the mFAM geometry) 2. Left atrial geometry creation time 3. Fluoroscopy time The clinical team will hypothesize that this approach will lead to accurate LA geometry creation more rapidly and using less fluoroscopy than standard techniques


Recruitment information / eligibility

Status Terminated
Enrollment 109
Est. completion date October 3, 2022
Est. primary completion date October 3, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Have AF as follows: 1. Paroxysmal AF - defined as AF that is non-sustained (terminate without electrical or pharmacologic cardioversion) lasting < 7 days. 2. Persistent AF - defined as AF that is sustained > 7 days. Episodes of AF which are terminated by electrical or pharmacologic cardioversion after = 48 hours of AF, but prior to 7 days, should also be classified as persistent AF episodes. - Are planned to undergo a first catheter ablation procedure (prior typical atrial flutter is allowed) - Have the ability to understand the requirements of the study and sign the informed consent form. - Are willing to adhere to study restrictions and comply with all post-procedural follow-up requirements Exclusion Criteria: - Rheumatic heart disease, - Current intra-cardiac thrombus - Class IV HF - Unable to sign consent - Unstable angina - Recent cerebral ischemic events - Contradiction to anticoagulation - Prior cardiac surgery - Complex congenital heart disease

Study Design


Intervention

Device:
MFAM
Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure. mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (2)

Lead Sponsor Collaborator
Vivek Reddy Biosense Webster, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary mMap Scoring Questionnaire mMap Scoring Questionnaire: Tool used by operators to rate the accuracy of the map based on the distance between ablation points and accuracy of anatomy compared to the mapped mFam geometry.
Total score from 1-7, with lower score indicating not representing (misleading) and higher score indicating agreement (accurate)
hospital discharge, average 24 hours post procedure
Secondary Left Atrial Geometry Creation Time The amount of time it takes to create the geometrical map using Carto and MFAM during the ablation procedure during the procedure up to 60 minutes
Secondary Fluoroscopy Time Fluoroscopy (radiation) time for left atrial anatomy creation during the ablation procedure hospital discharge, average 24 hours post procedure
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4